Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Dansk
English
!!Search content at Region Hovedstadens forskningsportal
Forside
Hospitaler/Afdelinger
Forskere
Publikationer
Aktiviteter
Priser
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Ramiro Garzon
, Michael Savona
, Rachid Baz
, Michael Andreeff
, Nashat Gabrail
, Martin Gutierrez
, Lynn Savoie
,
Paul Morten Mau-Sorensen
, Nina Wagner-Johnston
, Karen Yee
, Thaddeus J Unger
, Jean-Richard Saint-Martin
, Robert Carlson
, Tami Rashal
, Trinayan Kashyap
, Boris Klebanov
, Sharon Shacham
, Michael Kauffman
, Richard Stone
149
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Acute Myeloid Leukemia
100%
Phase 1 Clinical Trial
100%
Selinexor
100%
Hazard Ratio
40%
Adverse Events
40%
Objective Response
40%
Relapsed/refractory Acute Myeloid Leukemia
40%
Patient Demographics
20%
Twice Daily
20%
Clinical Development
20%
Monotherapy
20%
Safety Data
20%
Efficacy Data
20%
Overall Survival
20%
Hematological Malignancies
20%
Tumor Protein p53 (TP53)
20%
Supportive Care
20%
Dose-escalation Study
20%
Dose-limiting Toxicity
20%
Gastrointestinal Toxicity
20%
Non-responders
20%
Nuclear Accumulation
20%
Cancer Cell Death
20%
Cumulative Toxicity
20%
June 2014
20%
First-in-class
20%
XPO1
20%
Recommended Phase 2 Dose
20%
Exportin-1
20%
Nuclear Export Inhibitors
20%
Cycle Basis
20%
Bone Marrow Blast
20%
Median Progression-free Survival
20%
Class-selective
20%
Non-haematological
20%
Medicine and Dentistry
Clinical Trial
100%
Acute Myeloid Leukemia
100%
Selinexor
100%
Hazard Ratio
40%
Adverse Event
40%
Patient Population
20%
Cell Death
20%
Cancer Cell
20%
Overall Survival
20%
Monotherapy
20%
Progression Free Survival
20%
Hematologic Malignancy
20%
Supportive Care
20%
Isoprenaline
20%
Nuclear Export
20%
Gastrointestinal Toxicity
20%
Exportin 1
20%
Tumor Suppressor Protein
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Acute Myeloid Leukemia
100%
Selinexor
100%
Adverse Event
40%
Malignant Neoplasm
20%
Monotherapy
20%
Overall Survival
20%
Progression Free Survival
20%
Hematologic Malignancy
20%
Gastrointestinal Toxicity
20%
Isoprenaline
20%
Tumor Suppressor Protein
20%
Exportin 1
20%